NMIBC Risk Stratification (EAU)
ورودیهای بالینی بیمار
پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.
- Low—
- Intermediate—
- High—
- Very high—
The NMIBC Risk Stratification (EAU) calculates evaluating lower urinary tract symptoms, nephrolithiasis burden, and prostate cancer risk. Key inputs include tumor number. Scores guide initiating medical expulsive or alpha-blocker therapy, ordering renal imaging, or scheduling surgical intervention. This standardized assessment improves clinical decision safety and bedside patient management.
Clinical Guidelines & Evidence
EAU 2021 risk stratification for non-muscle-invasive bladder cancer (NMIBC): low, intermediate, high, or very high risk of recurrence/progression from tumor number, size, prior recurrence rate, T category, concomitant CIS, and grade.
Clinical Indication
The NMIBC Risk Stratification (EAU) is indicated for bedside clinical practice to support EAU 2021 risk stratification for non-muscle-invasive bladder cancer (NMIBC): low, intermediate, high, or very high risk of recurrence/progression from tumor number, size, prior recurrence rate, T category, concomitant CIS, and grade.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.
Target Population
Target population comprises Patients presenting with renal colic, hematuria, benign prostatic hyperplasia (BPH), or urogenital malignancies. Clinical application is indicated across Urology clinics, shock wave lithotripsy suites, and acute urologic surgical services.
Limitations & Contraindications
Serum PSA levels can be transiently elevated by acute prostatitis, urinary retention, or recent instrumentation.
Clinical Pearls & Action Plan
Obstructive urolithiasis complicated by upper urinary tract infection represents a surgical emergency requiring urgent decompression.
Very high: T1 + high grade + (CIS or multiple/recurrent/large). High: T1 or high grade/G3 or CIS or (multiple AND recurrent AND large Ta low-grade). Low: primary + solitary + Ta + low grade + <3 cm + no CIS. Intermediate: remainder.
Input Parameters
| Name | Type | Required | Description |
|---|---|---|---|
| tumor_number | string | Yes | Number of tumors |
| tumor_size | string | Yes | Largest tumor diameter |
| recurrence | string | Yes | Prior recurrence rate |
| t_category | string | Yes | T category |
| cis | string | Yes | Concomitant carcinoma in situ |
| grade | string | Yes | Tumor grade (WHO 2004/2016) |
Score Interpretation & Guidance
| Range | Stage | Description |
|---|---|---|
| — | Low | Low risk NMIBC |
| — | Intermediate | Intermediate risk NMIBC |
| — | High | High risk NMIBC |
| — | Very high | Very high risk NMIBC |
Evidence-Based References (EBM)
- Babjuk M, Burger M, Capitanio U, et al. European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and CIS). Eur Urol. 2022;81(1):75-94.